Navigation Links
Multidrop 384 (220-240 V)

ProductsMultidrop 384 (220-240 V)
Company ThermoFisher Scientific
Item Multidrop 384 (220-240 V)
Features Inquire
Description Multidrop 384 offers lower consumption of reagents and increased throughput, particularly for screening applications. The Multidrop 384 is an automated dispenser designed for high-throughput screening and microvolume dispensing into 384- and 96-well plates.This new-generation dispenser offers outstanding flexibility. It can easily switch from 96- to 384- well plates and dispense up to 8 different liquids simultaneously. High-speed continious dispensing.
Info ThermoFisher Scientific
Web site: http://www.thermo.com
Web site: http://www.thermofisher.com/global/en/home.asp

Related medicine products :

1. Multidrop 384 (110-120 V)
2. Multidrop DW (Deep Well) (220-240 V)
3. Multidrop DW (Deep Well) (110-120 V)
4. Multidrop Micro (220-240 V)
5. Multidrop Micro (110-120 V)
6. Wellwash 4 Mk2 (220-240 V AC/50 Hz)
7. Wellmix (220-240V)
8. ZOOM® Dual Power (220-240 VAC 47 - 60 Hz)
9. Model 583 Gel Dryer (220-240 V)
10. HydroTech™ Gel Drying System (220-240 V)
TAG: Multidrop
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 1Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 2Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 1Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 1ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 3ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 4ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 5ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 6ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 7ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 8ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 9ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 10ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 11